Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 2821 AL 2835

Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B

Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ.

J Neuroimmunol. 2011 Dec 15;240-241:121-8. doi: 10.1016/j.jneuroim.2011.10.005. Epub 2011 Nov 12.

Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease

Kalinderi K, Fidani L, Katsarou Z, Bostantjopoulou S.

Int J Clin Pract. 2011 Dec;65(12):1289-94. doi: 10.1111/j.1742-1241.2011.02793.x.

Tardive movement disorders: a practical approach

Saifee TA, Edwards MJ.

Pract Neurol. 2011 Dec;11(6):341-8. doi: 10.1136/practneurol-2011-000077.

Sleep in women

Pavlova M, Sheikh LS.

Semin Neurol. 2011 Sep;31(4):397-403. doi: 10.1055/s-0031-1293539. Epub 2011 Nov 23.

Genetic and biologic classification of infantile spasms

Paciorkowski AR, Thio LL, Dobyns WB.

Pediatr Neurol. 2011 Dec;45(6):355-67. doi: 10.1016/j.pediatrneurol.2011.08.010.

Atypical antipsychotic-induced weight gain: insights into mechanisms of action

Roerig JL, Steffen KJ, Mitchell JE.

CNS Drugs. 2011 Dec 1;25(12):1035-59. doi: 10.2165/11596300-000000000-00000.

Left-sided hemihypomimia in Parkinson's disease

Crosiers D, Maréchal E, van Ael Y, Cras P.

Acta Neurol Belg. 2011 Sep;111(3):225-7.

[French guidelines on the use of repetitive transcranial magnetic stimulation (rTMS): safety and therapeutic indications]

Lefaucheur JP, André-Obadia N, Poulet E, Devanne H, Haffen E, Londero A, Cretin B, Leroi AM, Radtchenko A, Saba G, Thai-Van H, Litré CF, Vercueil L, Bouhassira D, Ayache SS, Farhat WH, Zouari HG, Mylius V, Nicolier M, Garcia-Larrea L.

Neurophysiol Clin. 2011 Dec;41(5-6):221-95. doi: 10.1016/j.neucli.2011.10.062. Epub 2011 Nov 10.

Using non-coding small RNAs to develop therapies for Huntington's disease

Zhang Y, Friedlander RM.

Gene Ther. 2011 Dec;18(12):1139-49. doi: 10.1038/gt.2011.170.

Neurodegeneration across stages of cognitive decline in Parkinson disease

Weintraub D, Doshi J, Koka D, Davatzikos C, Siderowf AD, Duda JE, Wolk DA, Moberg PJ, Xie SX, Clark CM.

Arch Neurol. 2011 Dec;68(12):1562-8. doi: 10.1001/archneurol.2011.725.

Coenzyme Q10 for Parkinson's disease

Liu J, Wang L, Zhan SY, Xia Y.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD008150. doi: 10.1002/14651858.CD008150.pub2.

How best to address these common movement disorders

Yaman A, Akdeniz M, Yaman H.

J Fam Pract. 2011 Dec;60(12):721-5.

Pediatric periodic limb movement disorder: sleep symptom and polysomnographic correlates compared to obstructive sleep apnea

Gingras JL, Gaultney JF, Picchietti DL.

J Clin Sleep Med. 2011 Dec 15;7(6):603-9A. doi: 10.5664/jcsm.1460.

Movement disorders in 2011: Translating new research findings into clinical practice

Klein C, Krainc D.

Nat Rev Neurol. 2011 Dec 20;8(2):65-6. doi: 10.1038/nrneurol.2011.212.

Hemichorea-hemiballismus as an initial manifestation in a Moroccan patient with acquired immunodeficiency syndrome and toxoplasma infection: a case report and review of the literature

Rabhi S, Amrani K, Maaroufi M, Khammar Z, Khibri H, Ouazzani M, Berrady R, Tizniti S, Messouak O, Belahsen F, Bono W.

Pan Afr Med J. 2011;10:9. doi: 10.4314/pamj.v10i0.72216. Epub 2011 Sep 25.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias